Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1985-07

AUTHORS

D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, R. C. Turner

ABSTRACT

The steady-state basal plasma glucose and insulin concentrations are determined by their interaction in a feedback loop. A computer-solved model has been used to predict the homeostatic concentrations which arise from varying degrees of β-cell deficiency and insulin resistance. Comparison of a patient's fasting values with the model's predictions allows a quantitative assessment of the contributions of insulin resistance and deficient β-cell function to the fasting hyperglycaemia (homeostasis model assessment, HOMA). The accuracy and precision of the estimate have been determined by comparison with independent measures of insulin resistance and β-cell function using hyperglycaemic and euglycaemic clamps and an intravenous glucose tolerance test. The estimate of insulin resistance obtained by homeostasis model assessment correlated with estimates obtained by use of the euglycaemic clamp (Rs = 0.88, p < 0.0001), the fasting insulin concentration (Rs = 0.81, p < 0.0001), and the hyperglycaemic clamp, (Rs = 0.69, p < 0.01). There was no correlation with any aspect of insulin-receptor binding. The estimate of deficient β-cell function obtained by homeostasis model assessment correlated with that derived using the hyperglycaemic clamp (Rs = 0.61, p < 0.01) and with the estimate from the intravenous glucose tolerance test (Rs = 0.64, p < 0.05). The low precision of the estimates from the model (coefficients of variation: 31% for insulin resistance and 32% for β-cell deficit) limits its use, but the correlation of the model's estimates with patient data accords with the hypothesis that basal glucose and insulin interactions are largely determined by a simple feed back loop. More... »

PAGES

412-419

Journal

TITLE

Diabetologia

ISSUE

7

VOLUME

28

Clinical Trials linked to this publication

  • Do Innovative Strategies Complement Medical Management To Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?
  • Omentectomy For Treatment Of Diabetes Mellitus Type 2
  • Randomized Controlled Clinical Trial Of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
  • Efficacy Of Metformin Versus Sitagliptin On Benign Thyroid Nodules Size In Type 2 Diabetes: A 2-Years Prospective Multicentric Study
  • 1/2-Mc4r Genotype And Pediatric Antipsychotic Drug- Induced Weight Gain
  • Monitoring Of Metabolic Adverse Events Of Second Generation Antipsychotics In A Naive Pediatric Population Followed In Mental Health Outpatient And Inpatient Clinical Settings (Memas Prospective Study)
  • A Hiit To Improve Metabolic Health In Obese Adults With Insulin Resistance
  • Investigation For Health Efficacy Of Infrared-C Radiation On Diabetes Patients In Senior's Activity Center
  • Effect Of A Hypocaloric Diet With Different Glycemic Indexes On Ghrelin And Leptin Levels, Metabolic Parameters, And Reproductive Outcomes In Overweight And Obese Infertile Women: A Randomized Clinical Trial
  • The Effect Of Adrenergic Blocker Therapy On Cardiac And Striatal Transporter Uptake In Pre-Motor And Symptomatic Parkinson's Disease
  • Impact Of Vitamin D Supplementation On The Cardiometabolic Status And Androgen Profile In Women With Polycystic Ovary Syndrome: Placebo-Controlled Clinical Trial
  • Lifestyle Intervention In Preparation For Pregnancy (Lipp)
  • Sit Less, Interact, Move More (Slimm) Intervention For Sedentary Behavior In Chronic Kidney Disease (Ckd)
  • A Prospective, Randomized, Parallel-Group, Adaptive Design Phase Iib/Iii, Multicenter Study, To Assess The Efficacy Of Polychemotherapy For Inducing Remission Of Newly Diagnosed Type 2 Diabetes.
  • Inflammatory Mediators In Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial
  • Health Benefits Of Aerobic And Resistance Training In Individuals With Type 2 Diabetes
  • Evaluation Of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Ecf/Taf) Switch Followed By Ledipasvir-Sofosbuvir Hcv Therapy In Hiv-Hcv Co-Infection: A Cihr Canadian Hiv Trials Network-Gilead Pilot Trial Proposal
  • Essential Arterial Hypotension And Allostasis Registry
  • The Effect Of Acupuncture On Insulin Sensitivity Of Women With Polycystic Ovary Syndrome And Insulin Resistance: A Randomized Controlled Trial
  • Effect Of Coffee And Tea Consumption On Adolescent Weight Control - A Randomized Clinical Trial
  • A Pilot, Non-Comparative Study To Assess The Efficacy And Safety Of The New Food Supplement Fasemets In Metabolic Syndrome
  • The Effects Of Palm Oil Consumed Under Different Macronutrient Distributions On Circulating Lipoprotein And Fatty Acid Profiles
  • Modulation Of Insulin Secretion And Insulin Sensitivity In Bangladeshi Type 2 Diabetic Subjects By An Insulin Sensitizer Pioglitazone And T2dm Association With Pparg Gene Polymorphism.
  • Observational, Cross-Sectional, Longitudinal, Multi-Center, Diagnostic Study To Evaluate The Influence Of Acromegaly On Glucose Tolerance And To Evaluate The Changes Of Impaired Glucose Tolerance During Standard Treatment Of Acromegaly.
  • Related Patents

  • Combination Of An Insulin And A Glp-1 Agonist
  • Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes
  • Monitoring Glucose Metabolism By Measurement Of Exhaled Co2 Using Highly Enriched, Uniformly Labeled 13c-Glucose.
  • Dry Powder Inhaler And System For Drug Delivery
  • Canagliflozin, A Sodium-Glucose Transporter 2 Inhibitor As Antiobesity, Antidiabetic Agent; Purity; Handling Characteristics; Easy Formulation; Storage Stability
  • Dry Powder Inhaler And System For Drug Delivery
  • Single Nucleotide Polymorphism Associated With Risk Of Insulin Resistance Development
  • Process For The Preparation Of Compounds Useful As Inhibitors Of Sglt2
  • Dry Powder Drug Delivery System And Methods
  • Method Of Treating Diabetes Type 2 By Metformin And An Ultrarapid Acting Insulin
  • Dry Powder Inhaler And System For Drug Delivery
  • Glucopyranoside Compound
  • Co-Therapy Comprising Canagliflozin And Phentermine For The Treatment Of Obesity And Obesity Related Disorders
  • Method For Insulin Resistance Improving And A Method For Prevention Or Treatment Of Diabetes
  • Use Of Ultrarapid Acting Insulin
  • Methods For Preventing Or Treating Metabolic Syndrome
  • Biomarkers For Insulin Sensitizer Drug Response
  • Substituted Diketopiperazine Analogs For Use As Drug Delivery Agents
  • Dry Powder Drug Delivery System
  • Method For Improving The Pharmaceutic Properties Of Microparticles Comprising Diketopiperazine And An Active Agent
  • Substituted Diketopiperazine Analogs For Use As Drug Delivery Agents
  • Administering 13c-Enriched Glucose To Said Subject; Measuring The 13co2 In Each Of Said First And Second Breath Samples
  • Apparatus, System And Method For Measuring Resistance Of An Inhaler
  • Glucopyranoside Compound
  • Compounds Having An Isolated Peptide Consisting Of Structure (I)
  • Method Of Controlling Glycemia By Ultrarapid Acting Insulin Without Adjusting An Insulin Dose For Meal Content
  • Process For The Preparation Of Compounds Useful As Inhibitors Of Sglt
  • Diketopiperazine Salts For Drug Delivery And Related Methods
  • Methods And Compositions For Treatment Of Metabolic Disorders
  • Pharmaceutical Composition Comprising A Glp-1 Agonist, An Insulin And Methionine
  • 13c Glucose Breath Test For The Diagnosis Of Diabetic Indications And Monitoring Glycemic Control
  • Use Of Ultrarapid Acting Insulin
  • Determination Of A Tendency To Gain Weight
  • Use Of Ave0010 For The Treatment Of Diabetes Mellitus Type 2
  • Inhalable Vaccine Compositions And Methods
  • Method And Composition For Treating Migraines
  • Pharmaceutical Composition For Use In The Treatment Of A Neurodegenerative Disease
  • Interactive Apparatus And Method For Real-Time Profiling Of Inhalation Efforts
  • Substituted Diketopiperazine Analogs For Use As Drug Delivery Agents
  • Method And Index For Diagnosing Insulin Resistance
  • High Capacity Diketopiperazine Microparticles And Methods
  • 13c Glucose Breath Test For The Diagnosis Of Diabetic Indications And Monitoring Glycemic Control
  • Process For The Preparation Of Compounds Useful As Inhibitors Of Sglt2
  • Inhalation Apparatus
  • Method Of Drug Formulation Based On Increasing The Affinity Of Crystalline Microparticle Surfaces For Active Agents
  • Diketopiperazine Salts For Drug Delivery And Related Methods
  • Single Nucleotide Polymorphisms Associated With Dietary Weight Loss
  • Methods For Detecting Low Grade Inflammation
  • Dry Powder Inhaler And System For Drug Delivery
  • Glucopyranoside Compound
  • Crystallisation Process For 1-(Β-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene
  • Heat-Stable Dry Powder Pharmaceutical Compositions And Methods
  • Dry Powder Inhaler And System For Drug Delivery
  • Pharmaceutical Formulations
  • Red Blood Cell Dynamics For Gastrointestinal Evaluation
  • Treatment Of Type 2 Diabetes Mellitus Patients
  • Telomerase Reverse Transcriptase For Protection Against Ageing
  • Insulin Glargine/Lixisenatide Fixed Ratio Formulation
  • Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors
  • High Capacity Diketopiperazine Microparticles And Methods
  • Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease
  • L-Proline And Citric Acid Co-Crystals Of (2s, 3r, 4r, 5s,6r)-2-(3-((5-(4-Fluorophenyl)Thiopen-2-Yl)Methyl)4-Methylphenyl)-6-(Hydroxymethyl)Tetrahydro-2h-Pyran-3,4,5-Triol
  • Including The Antidiabetic, Antiobesity Sodium Glucose Transport Inhibitor Canagliflozin (1-( Beta -D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene)
  • Interactive Apparatus And Method For Real-Time Profiling Of Inhalation Efforts
  • Crystalline Form Of 1-(Β-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate
  • Pharmaceutical Composition Comprising A Glp-1-Agonist And Methionine
  • Methods And Compositions For Treating Pain
  • Novel Compound, Phosphorylation Inhibitor, Insulin Resistance Improving Agent, Agent To Prevent Or To Treat Diabetes, And Screening Method
  • Microcrystalline Diketopiperazine Compositions And Methods
  • Treatment Type 2 Diabetes Mellitus Patients
  • Reducing Risk Of Type 2 Diabetes (T2d)
  • Dry Powder Drug Delivery System And Methods
  • Screening Method For An Insulin Resistance Improving Agent Or A Therapeutic Agent For Diabetes
  • Insufflation Apparatus And Methods
  • Catalysis Of Diketopiperazine Synthesis
  • Methods And Compositions For Delivering Peptides
  • Method Of Treating Fatty Liver Diseases And Conditions In Non-Lipodystrophic Subjects
  • Methods Of Estimating Blood Glucose And Related Systems
  • Methods For Preventing Or Treating Metabolic Syndrome
  • Potentiation Of Glucose Elimination
  • Dry Powder Inhaler And System For Drug Delivery
  • Method For Improving The Pharmaceutic Properties Of Microparticles Comprising Diketopiperazine And An Active Agent
  • Methods For Preventing Or Treating Metabolic Syndrome
  • Potentiation Of Glucose Elimination
  • Apparatus And Method For Simulating Inhalation Efforts
  • Pharmaceutical Combination For Improving Glycemic Control As Add-On Therapy To Basal Insulin
  • Methods And Compositions For Treating Pain
  • Growth Differentiation Factor 15 As Biomarker For Metformin
  • Use Of Ultrarapid Acting Insulin
  • Use Of Ultrarapid Acting Insulin
  • Mouthpiece Cover For An Inhaler
  • Method Of Treating A Patient
  • Methods And Compositions For Treating Pain
  • Blister Package For Pharmaceutical Cartridges
  • Catalysis Of Diketopiperazine Synthesis
  • 13c Glucose Breath Test For The Diagnosis Of Diabetic Indications And Monitoring Glycemic Control
  • Method To Screen For An Activator Of Adipose-Resident Nk Cells
  • Biomarkers For Atherosclerosis
  • Diketopiperazine Microparticles With Defined Specific Surface Areas
  • Diagnosis And Complication Risk Assessment Of Pancreatic Diabetes Within Normal Value Ranges Of Leucocytes Using Procalcitonin
  • Methods And Compositions For Treating Pain
  • Blister Package For Pharmaceutical Cartridges
  • Diagnosis And Complication Risk Assessment Of Pancreatic Diabetes Within Normal Value Ranges Of Leucocytes Using Procalcitonin
  • Catalysis Of Diketopiperazine Synthesis
  • Method To Screen For An Activator Of Adipose-Resident Nk Cells
  • Biomarkers For Atherosclerosis
  • Use Of Ultrarapid Acting Insulin
  • Telomerase Reverse Transcriptase For Protection Against Ageing
  • Method Of Treating Diabetes Type 2 By Administering Ultrarapid Acting Insulin
  • White Blood Cell Population Dynamics
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf00280883

    DOI

    http://dx.doi.org/10.1007/bf00280883

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1027902786

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3899825


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Glucose", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Computers", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Erythrocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fasting", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Homeostasis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Insulin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Insulin Resistance", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Islets of Langerhans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Monocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, Insulin", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matthews", 
            "givenName": "D. R.", 
            "id": "sg:person.01216556762.76", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hosker", 
            "givenName": "J. P.", 
            "id": "sg:person.0716551025.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716551025.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rudenski", 
            "givenName": "A. S.", 
            "id": "sg:person.01156637623.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156637623.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Naylor", 
            "givenName": "B. A.", 
            "id": "sg:person.0627706757.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627706757.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Treacher", 
            "givenName": "D. F.", 
            "id": "sg:person.01015207513.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015207513.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK", 
              "id": "http://www.grid.ac/institutes/grid.8348.7", 
              "name": [
                "Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Turner", 
            "givenName": "R. C.", 
            "id": "sg:person.012177355252.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012177355252.09"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf00282705", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042771344", 
              "https://doi.org/10.1007/bf00282705"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00280882", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028857626", 
              "https://doi.org/10.1007/bf00280882"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00745134", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051373300", 
              "https://doi.org/10.1007/bf00745134"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1985-07", 
        "datePublishedReg": "1985-07-01", 
        "description": "The steady-state basal plasma glucose and insulin concentrations are determined by their interaction in a feedback loop. A computer-solved model has been used to predict the homeostatic concentrations which arise from varying degrees of \u03b2-cell deficiency and insulin resistance. Comparison of a patient's fasting values with the model's predictions allows a quantitative assessment of the contributions of insulin resistance and deficient \u03b2-cell function to the fasting hyperglycaemia (homeostasis model assessment, HOMA). The accuracy and precision of the estimate have been determined by comparison with independent measures of insulin resistance and \u03b2-cell function using hyperglycaemic and euglycaemic clamps and an intravenous glucose tolerance test. The estimate of insulin resistance obtained by homeostasis model assessment correlated with estimates obtained by use of the euglycaemic clamp (Rs = 0.88, p < 0.0001), the fasting insulin concentration (Rs = 0.81, p < 0.0001), and the hyperglycaemic clamp, (Rs = 0.69, p < 0.01). There was no correlation with any aspect of insulin-receptor binding. The estimate of deficient \u03b2-cell function obtained by homeostasis model assessment correlated with that derived using the hyperglycaemic clamp (Rs = 0.61, p < 0.01) and with the estimate from the intravenous glucose tolerance test (Rs = 0.64, p < 0.05). The low precision of the estimates from the model (coefficients of variation: 31% for insulin resistance and 32% for \u03b2-cell deficit) limits its use, but the correlation of the model's estimates with patient data accords with the hypothesis that basal glucose and insulin interactions are largely determined by a simple feed back loop.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf00280883", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1001482", 
            "issn": [
              "0012-186X", 
              "1432-0428"
            ], 
            "name": "Diabetologia", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "28"
          }
        ], 
        "keywords": [
          "\u03b2-cell function", 
          "intravenous glucose tolerance test", 
          "homeostasis model assessment", 
          "glucose tolerance test", 
          "insulin resistance", 
          "insulin concentrations", 
          "euglycaemic clamp", 
          "tolerance test", 
          "hyperglycaemic clamp", 
          "plasma glucose", 
          "model assessment", 
          "basal plasma glucose", 
          "insulin receptor binding", 
          "\u03b2-cell deficiency", 
          "clamp", 
          "glucose", 
          "homeostatic concentrations", 
          "hyperglycaemia", 
          "patients", 
          "assessment", 
          "insulin interaction", 
          "quantitative assessment", 
          "resistance", 
          "men", 
          "independent measures", 
          "concentration", 
          "deficiency", 
          "test", 
          "correlation", 
          "data accord", 
          "function", 
          "use", 
          "feedback loop", 
          "measures", 
          "binding", 
          "comparison", 
          "hypothesis", 
          "estimates", 
          "degree", 
          "interaction", 
          "model", 
          "aspects", 
          "loop", 
          "values", 
          "feed", 
          "prediction", 
          "contribution", 
          "model estimates", 
          "precision", 
          "accuracy", 
          "accord", 
          "low precision", 
          "model predictions", 
          "simple feed"
        ], 
        "name": "Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man", 
        "pagination": "412-419", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1027902786"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf00280883"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3899825"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf00280883", 
          "https://app.dimensions.ai/details/publication/pub.1027902786"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_215.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf00280883"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00280883'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00280883'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00280883'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00280883'


     

    This table displays all metadata directly associated to this object as RDF triples.

    218 TRIPLES      21 PREDICATES      97 URIs      86 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf00280883 schema:about N0ee4d3cbea6e4cb2adc5d5b6012ffc94
    2 N2f530bd712ee4ff99eb891874e102031
    3 N38d94ad3e5d64538bd3368779c95fbc6
    4 N7b98cd4dd62244e1b7d000f8768647f8
    5 N7f1aa3ba6f0242eb8d9874a4a3bd4c61
    6 N82434954148b48c88bb21b8aac5a0f76
    7 N9f234730d999433ba34e8889e8389769
    8 N9f622d9241e1473faa03a257fe76ba32
    9 Nb47f2754586c480298c4c39051a5f7fe
    10 Ncb35c309e4bd42aeb367f44020c4eec8
    11 Nd75d39368632496fa2ba302d4ee84104
    12 Nd938f2b42866442b93de57e600ae7be4
    13 Ndb6dab29d7744ed8825451071d94587d
    14 Ndbe295e11e564188a06d0f6043ee319f
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N750a907fb53b4baf9a5fc543c352aa46
    18 schema:citation sg:pub.10.1007/bf00280882
    19 sg:pub.10.1007/bf00282705
    20 sg:pub.10.1007/bf00745134
    21 schema:datePublished 1985-07
    22 schema:datePublishedReg 1985-07-01
    23 schema:description The steady-state basal plasma glucose and insulin concentrations are determined by their interaction in a feedback loop. A computer-solved model has been used to predict the homeostatic concentrations which arise from varying degrees of β-cell deficiency and insulin resistance. Comparison of a patient's fasting values with the model's predictions allows a quantitative assessment of the contributions of insulin resistance and deficient β-cell function to the fasting hyperglycaemia (homeostasis model assessment, HOMA). The accuracy and precision of the estimate have been determined by comparison with independent measures of insulin resistance and β-cell function using hyperglycaemic and euglycaemic clamps and an intravenous glucose tolerance test. The estimate of insulin resistance obtained by homeostasis model assessment correlated with estimates obtained by use of the euglycaemic clamp (Rs = 0.88, p < 0.0001), the fasting insulin concentration (Rs = 0.81, p < 0.0001), and the hyperglycaemic clamp, (Rs = 0.69, p < 0.01). There was no correlation with any aspect of insulin-receptor binding. The estimate of deficient β-cell function obtained by homeostasis model assessment correlated with that derived using the hyperglycaemic clamp (Rs = 0.61, p < 0.01) and with the estimate from the intravenous glucose tolerance test (Rs = 0.64, p < 0.05). The low precision of the estimates from the model (coefficients of variation: 31% for insulin resistance and 32% for β-cell deficit) limits its use, but the correlation of the model's estimates with patient data accords with the hypothesis that basal glucose and insulin interactions are largely determined by a simple feed back loop.
    24 schema:genre article
    25 schema:isAccessibleForFree true
    26 schema:isPartOf N57de596da657462ea3c1898a00482bd8
    27 Ne932564591eb4734894e32496bb8bc66
    28 sg:journal.1001482
    29 schema:keywords accord
    30 accuracy
    31 aspects
    32 assessment
    33 basal plasma glucose
    34 binding
    35 clamp
    36 comparison
    37 concentration
    38 contribution
    39 correlation
    40 data accord
    41 deficiency
    42 degree
    43 estimates
    44 euglycaemic clamp
    45 feed
    46 feedback loop
    47 function
    48 glucose
    49 glucose tolerance test
    50 homeostasis model assessment
    51 homeostatic concentrations
    52 hyperglycaemia
    53 hyperglycaemic clamp
    54 hypothesis
    55 independent measures
    56 insulin concentrations
    57 insulin interaction
    58 insulin receptor binding
    59 insulin resistance
    60 interaction
    61 intravenous glucose tolerance test
    62 loop
    63 low precision
    64 measures
    65 men
    66 model
    67 model assessment
    68 model estimates
    69 model predictions
    70 patients
    71 plasma glucose
    72 precision
    73 prediction
    74 quantitative assessment
    75 resistance
    76 simple feed
    77 test
    78 tolerance test
    79 use
    80 values
    81 β-cell deficiency
    82 β-cell function
    83 schema:name Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
    84 schema:pagination 412-419
    85 schema:productId N2e524ebf402a47988ee4d80df45ac70a
    86 N87db5d85ab3141f0a5a36b4b984667ef
    87 Nb7de4862b4054514ad7e6eca35f08d5e
    88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027902786
    89 https://doi.org/10.1007/bf00280883
    90 schema:sdDatePublished 2022-12-01T06:19
    91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    92 schema:sdPublisher N9517e55526f543dcac922480751903fe
    93 schema:url https://doi.org/10.1007/bf00280883
    94 sgo:license sg:explorer/license/
    95 sgo:sdDataset articles
    96 rdf:type schema:ScholarlyArticle
    97 N0e95896f90d74c27990c551e424c411b rdf:first sg:person.01015207513.12
    98 rdf:rest N722af870a6e840319c11ba9befa71352
    99 N0ee4d3cbea6e4cb2adc5d5b6012ffc94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    100 schema:name Erythrocytes
    101 rdf:type schema:DefinedTerm
    102 N2e524ebf402a47988ee4d80df45ac70a schema:name dimensions_id
    103 schema:value pub.1027902786
    104 rdf:type schema:PropertyValue
    105 N2f530bd712ee4ff99eb891874e102031 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Diabetes Mellitus, Type 2
    107 rdf:type schema:DefinedTerm
    108 N38d94ad3e5d64538bd3368779c95fbc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Insulin
    110 rdf:type schema:DefinedTerm
    111 N57de596da657462ea3c1898a00482bd8 schema:volumeNumber 28
    112 rdf:type schema:PublicationVolume
    113 N6b4aa51e8ac942848299c7df7b2cb913 rdf:first sg:person.01156637623.46
    114 rdf:rest Nc4892bd2770c4c08ae15fef3fd8e4ce6
    115 N722af870a6e840319c11ba9befa71352 rdf:first sg:person.012177355252.09
    116 rdf:rest rdf:nil
    117 N750a907fb53b4baf9a5fc543c352aa46 rdf:first sg:person.01216556762.76
    118 rdf:rest Nafa1110f805a4327aa6319c6c82b65a0
    119 N7b98cd4dd62244e1b7d000f8768647f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Adult
    121 rdf:type schema:DefinedTerm
    122 N7f1aa3ba6f0242eb8d9874a4a3bd4c61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Middle Aged
    124 rdf:type schema:DefinedTerm
    125 N82434954148b48c88bb21b8aac5a0f76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Islets of Langerhans
    127 rdf:type schema:DefinedTerm
    128 N87db5d85ab3141f0a5a36b4b984667ef schema:name doi
    129 schema:value 10.1007/bf00280883
    130 rdf:type schema:PropertyValue
    131 N9517e55526f543dcac922480751903fe schema:name Springer Nature - SN SciGraph project
    132 rdf:type schema:Organization
    133 N9f234730d999433ba34e8889e8389769 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Fasting
    135 rdf:type schema:DefinedTerm
    136 N9f622d9241e1473faa03a257fe76ba32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Computers
    138 rdf:type schema:DefinedTerm
    139 Nafa1110f805a4327aa6319c6c82b65a0 rdf:first sg:person.0716551025.95
    140 rdf:rest N6b4aa51e8ac942848299c7df7b2cb913
    141 Nb47f2754586c480298c4c39051a5f7fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Insulin Resistance
    143 rdf:type schema:DefinedTerm
    144 Nb7de4862b4054514ad7e6eca35f08d5e schema:name pubmed_id
    145 schema:value 3899825
    146 rdf:type schema:PropertyValue
    147 Nc4892bd2770c4c08ae15fef3fd8e4ce6 rdf:first sg:person.0627706757.89
    148 rdf:rest N0e95896f90d74c27990c551e424c411b
    149 Ncb35c309e4bd42aeb367f44020c4eec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Homeostasis
    151 rdf:type schema:DefinedTerm
    152 Nd75d39368632496fa2ba302d4ee84104 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Receptor, Insulin
    154 rdf:type schema:DefinedTerm
    155 Nd938f2b42866442b93de57e600ae7be4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Blood Glucose
    157 rdf:type schema:DefinedTerm
    158 Ndb6dab29d7744ed8825451071d94587d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Humans
    160 rdf:type schema:DefinedTerm
    161 Ndbe295e11e564188a06d0f6043ee319f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Monocytes
    163 rdf:type schema:DefinedTerm
    164 Ne932564591eb4734894e32496bb8bc66 schema:issueNumber 7
    165 rdf:type schema:PublicationIssue
    166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    167 schema:name Medical and Health Sciences
    168 rdf:type schema:DefinedTerm
    169 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    170 schema:name Clinical Sciences
    171 rdf:type schema:DefinedTerm
    172 sg:journal.1001482 schema:issn 0012-186X
    173 1432-0428
    174 schema:name Diabetologia
    175 schema:publisher Springer Nature
    176 rdf:type schema:Periodical
    177 sg:person.01015207513.12 schema:affiliation grid-institutes:grid.8348.7
    178 schema:familyName Treacher
    179 schema:givenName D. F.
    180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015207513.12
    181 rdf:type schema:Person
    182 sg:person.01156637623.46 schema:affiliation grid-institutes:grid.8348.7
    183 schema:familyName Rudenski
    184 schema:givenName A. S.
    185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156637623.46
    186 rdf:type schema:Person
    187 sg:person.01216556762.76 schema:affiliation grid-institutes:grid.8348.7
    188 schema:familyName Matthews
    189 schema:givenName D. R.
    190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76
    191 rdf:type schema:Person
    192 sg:person.012177355252.09 schema:affiliation grid-institutes:grid.8348.7
    193 schema:familyName Turner
    194 schema:givenName R. C.
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012177355252.09
    196 rdf:type schema:Person
    197 sg:person.0627706757.89 schema:affiliation grid-institutes:grid.8348.7
    198 schema:familyName Naylor
    199 schema:givenName B. A.
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627706757.89
    201 rdf:type schema:Person
    202 sg:person.0716551025.95 schema:affiliation grid-institutes:grid.8348.7
    203 schema:familyName Hosker
    204 schema:givenName J. P.
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716551025.95
    206 rdf:type schema:Person
    207 sg:pub.10.1007/bf00280882 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028857626
    208 https://doi.org/10.1007/bf00280882
    209 rdf:type schema:CreativeWork
    210 sg:pub.10.1007/bf00282705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042771344
    211 https://doi.org/10.1007/bf00282705
    212 rdf:type schema:CreativeWork
    213 sg:pub.10.1007/bf00745134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051373300
    214 https://doi.org/10.1007/bf00745134
    215 rdf:type schema:CreativeWork
    216 grid-institutes:grid.8348.7 schema:alternateName Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK
    217 schema:name Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK
    218 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...